Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 107(2020), 11 vom: 01. Nov., Seite 1085-1086 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
AMM : entrectinib et larotrectinib – cancers avec fusion NTRK |
|---|
| Beteiligte Personen: |
Delaye, Matthieu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.02.2021 Date Revised 03.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bulcan.2020.09.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317374214 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317374214 | ||
| 003 | DE-627 | ||
| 005 | 20231225163130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2020.09.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1057.xml |
| 035 | |a (DE-627)NLM317374214 | ||
| 035 | |a (NLM)33169692 | ||
| 035 | |a (PII)S0007-4551(20)30407-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Delaye, Matthieu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug approval |b entrectinib and larotrectinib - cancers with NTRK fusion |
| 246 | 3 | 3 | |a AMM : entrectinib et larotrectinib – cancers avec fusion NTRK |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.02.2021 | ||
| 500 | |a Date Revised 03.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a News | |
| 650 | 7 | |a Benzamides |2 NLM | |
| 650 | 7 | |a Indazoles |2 NLM | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 650 | 7 | |a NTRK1 protein, human |2 NLM | |
| 650 | 7 | |a NTRK3 protein, human |2 NLM | |
| 650 | 7 | |a Oncogene Proteins, Fusion |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Receptor, trkA |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, trkB |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, trkC |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a tropomyosin-related kinase-B, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a entrectinib |2 NLM | |
| 650 | 7 | |a L5ORF0AN1I |2 NLM | |
| 650 | 7 | |a larotrectinib |2 NLM | |
| 650 | 7 | |a PF9462I9HX |2 NLM | |
| 700 | 1 | |a Rodrigues, Manuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 107(2020), 11 vom: 01. Nov., Seite 1085-1086 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2020 |g number:11 |g day:01 |g month:11 |g pages:1085-1086 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2020.09.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2020 |e 11 |b 01 |c 11 |h 1085-1086 | ||